Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449840 | 0.87 | PTGER1 (0.44) | PTGER1HSD11B1 | |
| SCHEMBL6451311 | 0.82 | SYK (0.40) | SYKSGMS2HSD11B1LRRK2NPC1 | |
| SCHEMBL6528085 | 0.81 | SYK (0.48) | PTGER1SYKSGMS2LRRK2GSK3B | |
| SCHEMBL6450885 | 0.80 | HSD11B1 (0.43) | HSD11B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6448858 | 0.73 | SYK (0.55) | PTGER1SYKSGMS2MAOBTSHR | |
| SCHEMBL753616 | 0.73 | MAOB (0.54) | GSK3BCDK5CDK5R1MAOBABCB1 | |
| SCHEMBL1094535 | 0.72 | SCN9A (0.47) | PTGER1LRRK2 | |
| SCHEMBL6449875 | 0.69 | PTGER1 (0.45) | PTGER1HSD11B1LRRK2CYP1A2 | |
| SCHEMBL6454291 | 0.68 | HTT (0.42) | SYKSGMS2CYP1A2CYP3A4 | |
| SCHEMBL8557138 | 0.67 | MRGPRX4 (0.44) | PTGER1CYP3A4MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | PTGER1 3096/4885SYK 4094/4885SGMS2 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.